nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP2C8—Vismodegib—skin cancer	0.08	0.116	CbGbCtD
Cyclophosphamide—CYP2C19—Vismodegib—skin cancer	0.0671	0.0973	CbGbCtD
Cyclophosphamide—CYP2A6—Fluorouracil—skin cancer	0.0576	0.0836	CbGbCtD
Cyclophosphamide—CYP2C9—Vismodegib—skin cancer	0.0558	0.0809	CbGbCtD
Cyclophosphamide—ABCB1—Vismodegib—skin cancer	0.0542	0.0785	CbGbCtD
Cyclophosphamide—CYP3A4—Temozolomide—skin cancer	0.0468	0.0679	CbGbCtD
Cyclophosphamide—CYP3A4—Imiquimod—skin cancer	0.0468	0.0679	CbGbCtD
Cyclophosphamide—CYP2D6—Vemurafenib—skin cancer	0.0403	0.0585	CbGbCtD
Cyclophosphamide—CYP3A4—Vismodegib—skin cancer	0.0325	0.047	CbGbCtD
Cyclophosphamide—CYP3A7—Docetaxel—skin cancer	0.0301	0.0436	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0301	0.0436	CbGbCtD
Cyclophosphamide—ABCB1—Dactinomycin—skin cancer	0.0285	0.0412	CbGbCtD
Cyclophosphamide—CYP2C8—Fluorouracil—skin cancer	0.0284	0.0412	CbGbCtD
Cyclophosphamide—CYP3A4—Vemurafenib—skin cancer	0.0257	0.0372	CbGbCtD
Cyclophosphamide—CYP3A5—Docetaxel—skin cancer	0.0226	0.0327	CbGbCtD
Cyclophosphamide—CYP2C9—Fluorouracil—skin cancer	0.0198	0.0287	CbGbCtD
Cyclophosphamide—ABCB1—Docetaxel—skin cancer	0.0147	0.0213	CbGbCtD
Cyclophosphamide—CYP3A4—Docetaxel—skin cancer	0.0088	0.0128	CbGbCtD
Cyclophosphamide—Fatigue—Imiquimod—skin cancer	0.000255	0.000822	CcSEcCtD
Cyclophosphamide—Menopausal symptoms—Docetaxel—skin cancer	0.000254	0.000819	CcSEcCtD
Cyclophosphamide—Atrial fibrillation—Docetaxel—skin cancer	0.000253	0.000816	CcSEcCtD
Cyclophosphamide—Pain—Imiquimod—skin cancer	0.000253	0.000815	CcSEcCtD
Cyclophosphamide—Acute coronary syndrome—Fluorouracil—skin cancer	0.000252	0.000814	CcSEcCtD
Cyclophosphamide—Renal impairment—Docetaxel—skin cancer	0.000252	0.000812	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Fluorouracil—skin cancer	0.000251	0.000809	CcSEcCtD
Cyclophosphamide—Myocardial infarction—Fluorouracil—skin cancer	0.000251	0.000809	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Docetaxel—skin cancer	0.000251	0.000809	CcSEcCtD
Cyclophosphamide—Haemoglobin—Temozolomide—skin cancer	0.000251	0.000808	CcSEcCtD
Cyclophosphamide—Stomatitis—Fluorouracil—skin cancer	0.00025	0.000804	CcSEcCtD
Cyclophosphamide—Hepatitis—Temozolomide—skin cancer	0.000249	0.000804	CcSEcCtD
Cyclophosphamide—Haemorrhage—Temozolomide—skin cancer	0.000249	0.000804	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Fluorouracil—skin cancer	0.000249	0.000802	CcSEcCtD
Cyclophosphamide—Asthenia—Vemurafenib—skin cancer	0.000249	0.000802	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Temozolomide—skin cancer	0.000248	0.0008	CcSEcCtD
Cyclophosphamide—Chills—Dactinomycin—skin cancer	0.000247	0.000798	CcSEcCtD
Cyclophosphamide—Cardiac failure—Docetaxel—skin cancer	0.000246	0.000792	CcSEcCtD
Cyclophosphamide—Pruritus—Vemurafenib—skin cancer	0.000245	0.000791	CcSEcCtD
Cyclophosphamide—Alopecia—Dactinomycin—skin cancer	0.000244	0.000786	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Imiquimod—skin cancer	0.000244	0.000786	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Docetaxel—skin cancer	0.000241	0.000776	CcSEcCtD
Cyclophosphamide—Visual impairment—Temozolomide—skin cancer	0.00024	0.000775	CcSEcCtD
Cyclophosphamide—Erythema—Dactinomycin—skin cancer	0.00024	0.000774	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.00024	0.000773	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Fluorouracil—skin cancer	0.000239	0.00077	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Bleomycin—skin cancer	0.000239	0.00077	CcSEcCtD
Cyclophosphamide—Anaemia—Bleomycin—skin cancer	0.000238	0.000767	CcSEcCtD
Cyclophosphamide—Diarrhoea—Vemurafenib—skin cancer	0.000237	0.000765	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Temozolomide—skin cancer	0.000236	0.00076	CcSEcCtD
Cyclophosphamide—Urticaria—Imiquimod—skin cancer	0.000235	0.000757	CcSEcCtD
Cyclophosphamide—Body temperature increased—Imiquimod—skin cancer	0.000234	0.000754	CcSEcCtD
Cyclophosphamide—Tinnitus—Temozolomide—skin cancer	0.000233	0.00075	CcSEcCtD
Cyclophosphamide—Malaise—Bleomycin—skin cancer	0.000232	0.000748	CcSEcCtD
Cyclophosphamide—Flushing—Temozolomide—skin cancer	0.000231	0.000746	CcSEcCtD
Cyclophosphamide—Haemoglobin—Fluorouracil—skin cancer	0.000231	0.000745	CcSEcCtD
Cyclophosphamide—Leukopenia—Bleomycin—skin cancer	0.00023	0.000743	CcSEcCtD
Cyclophosphamide—Rhinitis—Fluorouracil—skin cancer	0.00023	0.000743	CcSEcCtD
Cyclophosphamide—Haemorrhage—Fluorouracil—skin cancer	0.00023	0.000741	CcSEcCtD
Cyclophosphamide—Dizziness—Vemurafenib—skin cancer	0.000229	0.000739	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Fluorouracil—skin cancer	0.000229	0.000737	CcSEcCtD
Cyclophosphamide—Cough—Bleomycin—skin cancer	0.000225	0.000724	CcSEcCtD
Cyclophosphamide—Chills—Temozolomide—skin cancer	0.000224	0.000721	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Dactinomycin—skin cancer	0.000223	0.000718	CcSEcCtD
Cyclophosphamide—Anaemia—Dactinomycin—skin cancer	0.000222	0.000715	CcSEcCtD
Cyclophosphamide—Vomiting—Vemurafenib—skin cancer	0.00022	0.000711	CcSEcCtD
Cyclophosphamide—Alopecia—Temozolomide—skin cancer	0.00022	0.000711	CcSEcCtD
Cyclophosphamide—Myalgia—Bleomycin—skin cancer	0.000219	0.000706	CcSEcCtD
Cyclophosphamide—Chest pain—Bleomycin—skin cancer	0.000219	0.000706	CcSEcCtD
Cyclophosphamide—Rash—Vemurafenib—skin cancer	0.000219	0.000705	CcSEcCtD
Cyclophosphamide—Dermatitis—Vemurafenib—skin cancer	0.000218	0.000704	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Imiquimod—skin cancer	0.000218	0.000702	CcSEcCtD
Cyclophosphamide—Headache—Vemurafenib—skin cancer	0.000217	0.0007	CcSEcCtD
Cyclophosphamide—Erythema—Temozolomide—skin cancer	0.000217	0.0007	CcSEcCtD
Cyclophosphamide—Discomfort—Bleomycin—skin cancer	0.000217	0.000698	CcSEcCtD
Cyclophosphamide—Malaise—Dactinomycin—skin cancer	0.000216	0.000698	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000216	0.000696	CcSEcCtD
Cyclophosphamide—Leukopenia—Dactinomycin—skin cancer	0.000215	0.000693	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Docetaxel—skin cancer	0.000214	0.000691	CcSEcCtD
Cyclophosphamide—Dysgeusia—Temozolomide—skin cancer	0.000213	0.000685	CcSEcCtD
Cyclophosphamide—Asthenia—Imiquimod—skin cancer	0.000212	0.000684	CcSEcCtD
Cyclophosphamide—Confusional state—Bleomycin—skin cancer	0.000212	0.000683	CcSEcCtD
Cyclophosphamide—Oedema—Bleomycin—skin cancer	0.00021	0.000677	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Bleomycin—skin cancer	0.00021	0.000677	CcSEcCtD
Cyclophosphamide—Pruritus—Imiquimod—skin cancer	0.000209	0.000674	CcSEcCtD
Cyclophosphamide—Infection—Bleomycin—skin cancer	0.000209	0.000673	CcSEcCtD
Cyclophosphamide—Nausea—Vemurafenib—skin cancer	0.000206	0.000664	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Bleomycin—skin cancer	0.000206	0.000663	CcSEcCtD
Cyclophosphamide—Arrhythmia—Fluorouracil—skin cancer	0.000205	0.000662	CcSEcCtD
Cyclophosphamide—Vision blurred—Temozolomide—skin cancer	0.000205	0.00066	CcSEcCtD
Cyclophosphamide—Myalgia—Dactinomycin—skin cancer	0.000204	0.000659	CcSEcCtD
Cyclophosphamide—Bronchospasm—Docetaxel—skin cancer	0.000204	0.000657	CcSEcCtD
Cyclophosphamide—Tremor—Temozolomide—skin cancer	0.000203	0.000656	CcSEcCtD
Cyclophosphamide—Alopecia—Fluorouracil—skin cancer	0.000203	0.000655	CcSEcCtD
Cyclophosphamide—Diarrhoea—Imiquimod—skin cancer	0.000202	0.000652	CcSEcCtD
Cyclophosphamide—Discomfort—Dactinomycin—skin cancer	0.000202	0.000651	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Temozolomide—skin cancer	0.000201	0.000649	CcSEcCtD
Cyclophosphamide—Anaemia—Temozolomide—skin cancer	0.000201	0.000647	CcSEcCtD
Cyclophosphamide—Anorexia—Bleomycin—skin cancer	0.0002	0.000646	CcSEcCtD
Cyclophosphamide—Erythema—Fluorouracil—skin cancer	0.0002	0.000645	CcSEcCtD
Cyclophosphamide—Agitation—Temozolomide—skin cancer	0.0002	0.000643	CcSEcCtD
Cyclophosphamide—Pancytopenia—Docetaxel—skin cancer	0.000197	0.000634	CcSEcCtD
Cyclophosphamide—Hypotension—Bleomycin—skin cancer	0.000196	0.000633	CcSEcCtD
Cyclophosphamide—Oedema—Dactinomycin—skin cancer	0.000196	0.000632	CcSEcCtD
Cyclophosphamide—Malaise—Temozolomide—skin cancer	0.000196	0.000631	CcSEcCtD
Cyclophosphamide—Dizziness—Imiquimod—skin cancer	0.000196	0.00063	CcSEcCtD
Cyclophosphamide—Infection—Dactinomycin—skin cancer	0.000195	0.000627	CcSEcCtD
Cyclophosphamide—Leukopenia—Temozolomide—skin cancer	0.000194	0.000627	CcSEcCtD
Cyclophosphamide—Palpitations—Temozolomide—skin cancer	0.000192	0.000619	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Dactinomycin—skin cancer	0.000192	0.000618	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000191	0.000617	CcSEcCtD
Cyclophosphamide—Cough—Temozolomide—skin cancer	0.000189	0.000611	CcSEcCtD
Cyclophosphamide—Paraesthesia—Bleomycin—skin cancer	0.000189	0.000608	CcSEcCtD
Cyclophosphamide—Weight increased—Docetaxel—skin cancer	0.000189	0.000608	CcSEcCtD
Cyclophosphamide—Vision blurred—Fluorouracil—skin cancer	0.000189	0.000608	CcSEcCtD
Cyclophosphamide—Convulsion—Temozolomide—skin cancer	0.000188	0.000606	CcSEcCtD
Cyclophosphamide—Vomiting—Imiquimod—skin cancer	0.000188	0.000606	CcSEcCtD
Cyclophosphamide—Hypertension—Temozolomide—skin cancer	0.000187	0.000604	CcSEcCtD
Cyclophosphamide—Dyspnoea—Bleomycin—skin cancer	0.000187	0.000604	CcSEcCtD
Cyclophosphamide—Anorexia—Dactinomycin—skin cancer	0.000187	0.000602	CcSEcCtD
Cyclophosphamide—Rash—Imiquimod—skin cancer	0.000186	0.000601	CcSEcCtD
Cyclophosphamide—Dermatitis—Imiquimod—skin cancer	0.000186	0.000601	CcSEcCtD
Cyclophosphamide—Pneumonia—Docetaxel—skin cancer	0.000186	0.000599	CcSEcCtD
Cyclophosphamide—Headache—Imiquimod—skin cancer	0.000185	0.000597	CcSEcCtD
Cyclophosphamide—Anaemia—Fluorouracil—skin cancer	0.000185	0.000596	CcSEcCtD
Cyclophosphamide—Myalgia—Temozolomide—skin cancer	0.000185	0.000596	CcSEcCtD
Cyclophosphamide—Arthralgia—Temozolomide—skin cancer	0.000185	0.000596	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000183	0.000591	CcSEcCtD
Cyclophosphamide—Discomfort—Temozolomide—skin cancer	0.000183	0.000589	CcSEcCtD
Cyclophosphamide—Decreased appetite—Bleomycin—skin cancer	0.000183	0.000589	CcSEcCtD
Cyclophosphamide—Acute coronary syndrome—Docetaxel—skin cancer	0.000182	0.000587	CcSEcCtD
Cyclophosphamide—Renal failure—Docetaxel—skin cancer	0.000182	0.000586	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Docetaxel—skin cancer	0.000181	0.000584	CcSEcCtD
Cyclophosphamide—Myocardial infarction—Docetaxel—skin cancer	0.000181	0.000584	CcSEcCtD
Cyclophosphamide—Stomatitis—Docetaxel—skin cancer	0.00018	0.000581	CcSEcCtD
Cyclophosphamide—Jaundice—Docetaxel—skin cancer	0.00018	0.000581	CcSEcCtD
Cyclophosphamide—Pain—Bleomycin—skin cancer	0.00018	0.000579	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Docetaxel—skin cancer	0.00018	0.000579	CcSEcCtD
Cyclophosphamide—Leukopenia—Fluorouracil—skin cancer	0.000179	0.000577	CcSEcCtD
Cyclophosphamide—Confusional state—Temozolomide—skin cancer	0.000179	0.000576	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000178	0.000575	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Temozolomide—skin cancer	0.000177	0.000571	CcSEcCtD
Cyclophosphamide—Oedema—Temozolomide—skin cancer	0.000177	0.000571	CcSEcCtD
Cyclophosphamide—Infection—Temozolomide—skin cancer	0.000176	0.000568	CcSEcCtD
Cyclophosphamide—Nausea—Imiquimod—skin cancer	0.000176	0.000566	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Temozolomide—skin cancer	0.000173	0.000559	CcSEcCtD
Cyclophosphamide—Convulsion—Fluorouracil—skin cancer	0.000173	0.000559	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Bleomycin—skin cancer	0.000173	0.000558	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Docetaxel—skin cancer	0.000172	0.000556	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Temozolomide—skin cancer	0.000171	0.000552	CcSEcCtD
Cyclophosphamide—Myalgia—Fluorouracil—skin cancer	0.00017	0.000549	CcSEcCtD
Cyclophosphamide—Chest pain—Fluorouracil—skin cancer	0.00017	0.000549	CcSEcCtD
Cyclophosphamide—Decreased appetite—Dactinomycin—skin cancer	0.00017	0.000549	CcSEcCtD
Cyclophosphamide—Fatigue—Dactinomycin—skin cancer	0.000169	0.000545	CcSEcCtD
Cyclophosphamide—Anorexia—Temozolomide—skin cancer	0.000169	0.000545	CcSEcCtD
Cyclophosphamide—Discomfort—Fluorouracil—skin cancer	0.000168	0.000542	CcSEcCtD
Cyclophosphamide—Pain—Dactinomycin—skin cancer	0.000168	0.00054	CcSEcCtD
Cyclophosphamide—Urticaria—Bleomycin—skin cancer	0.000167	0.000538	CcSEcCtD
Cyclophosphamide—Haemoglobin—Docetaxel—skin cancer	0.000167	0.000537	CcSEcCtD
Cyclophosphamide—Rhinitis—Docetaxel—skin cancer	0.000166	0.000536	CcSEcCtD
Cyclophosphamide—Body temperature increased—Bleomycin—skin cancer	0.000166	0.000535	CcSEcCtD
Cyclophosphamide—Haemorrhage—Docetaxel—skin cancer	0.000166	0.000535	CcSEcCtD
Cyclophosphamide—Hepatitis—Docetaxel—skin cancer	0.000166	0.000535	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Docetaxel—skin cancer	0.000165	0.000532	CcSEcCtD
Cyclophosphamide—Confusional state—Fluorouracil—skin cancer	0.000165	0.000531	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Fluorouracil—skin cancer	0.000163	0.000526	CcSEcCtD
Cyclophosphamide—Oedema—Fluorouracil—skin cancer	0.000163	0.000526	CcSEcCtD
Cyclophosphamide—Infection—Fluorouracil—skin cancer	0.000162	0.000523	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Dactinomycin—skin cancer	0.000161	0.00052	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000161	0.00052	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Fluorouracil—skin cancer	0.00016	0.000515	CcSEcCtD
Cyclophosphamide—Visual impairment—Docetaxel—skin cancer	0.00016	0.000515	CcSEcCtD
Cyclophosphamide—Tachycardia—Fluorouracil—skin cancer	0.000159	0.000514	CcSEcCtD
Cyclophosphamide—Paraesthesia—Temozolomide—skin cancer	0.000159	0.000513	CcSEcCtD
Cyclophosphamide—Dyspnoea—Temozolomide—skin cancer	0.000158	0.000509	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Docetaxel—skin cancer	0.000157	0.000506	CcSEcCtD
Cyclophosphamide—Anorexia—Fluorouracil—skin cancer	0.000156	0.000502	CcSEcCtD
Cyclophosphamide—Body temperature increased—Dactinomycin—skin cancer	0.000155	0.000499	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Bleomycin—skin cancer	0.000155	0.000499	CcSEcCtD
Cyclophosphamide—Decreased appetite—Temozolomide—skin cancer	0.000154	0.000497	CcSEcCtD
Cyclophosphamide—Flushing—Docetaxel—skin cancer	0.000154	0.000496	CcSEcCtD
Cyclophosphamide—Fatigue—Temozolomide—skin cancer	0.000153	0.000493	CcSEcCtD
Cyclophosphamide—Hypotension—Fluorouracil—skin cancer	0.000153	0.000492	CcSEcCtD
Cyclophosphamide—Constipation—Temozolomide—skin cancer	0.000152	0.000489	CcSEcCtD
Cyclophosphamide—Pain—Temozolomide—skin cancer	0.000152	0.000489	CcSEcCtD
Cyclophosphamide—Asthenia—Bleomycin—skin cancer	0.000151	0.000486	CcSEcCtD
Cyclophosphamide—Chills—Docetaxel—skin cancer	0.000149	0.00048	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000149	0.00048	CcSEcCtD
Cyclophosphamide—Pruritus—Bleomycin—skin cancer	0.000149	0.000479	CcSEcCtD
Cyclophosphamide—Arrhythmia—Docetaxel—skin cancer	0.000148	0.000478	CcSEcCtD
Cyclophosphamide—Paraesthesia—Fluorouracil—skin cancer	0.000147	0.000473	CcSEcCtD
Cyclophosphamide—Alopecia—Docetaxel—skin cancer	0.000147	0.000473	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Temozolomide—skin cancer	0.000146	0.000471	CcSEcCtD
Cyclophosphamide—Dyspnoea—Fluorouracil—skin cancer	0.000146	0.000469	CcSEcCtD
Cyclophosphamide—Erythema—Docetaxel—skin cancer	0.000144	0.000465	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Dactinomycin—skin cancer	0.000144	0.000465	CcSEcCtD
Cyclophosphamide—Decreased appetite—Fluorouracil—skin cancer	0.000142	0.000458	CcSEcCtD
Cyclophosphamide—Dysgeusia—Docetaxel—skin cancer	0.000141	0.000456	CcSEcCtD
Cyclophosphamide—Urticaria—Temozolomide—skin cancer	0.000141	0.000454	CcSEcCtD
Cyclophosphamide—Asthenia—Dactinomycin—skin cancer	0.000141	0.000453	CcSEcCtD
Cyclophosphamide—Body temperature increased—Temozolomide—skin cancer	0.00014	0.000452	CcSEcCtD
Cyclophosphamide—Pain—Fluorouracil—skin cancer	0.00014	0.00045	CcSEcCtD
Cyclophosphamide—Muscle spasms—Docetaxel—skin cancer	0.000139	0.000448	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Fluorouracil—skin cancer	0.000135	0.000434	CcSEcCtD
Cyclophosphamide—Diarrhoea—Dactinomycin—skin cancer	0.000134	0.000432	CcSEcCtD
Cyclophosphamide—Vomiting—Bleomycin—skin cancer	0.000134	0.000431	CcSEcCtD
Cyclophosphamide—Anaemia—Docetaxel—skin cancer	0.000133	0.00043	CcSEcCtD
Cyclophosphamide—Rash—Bleomycin—skin cancer	0.000132	0.000427	CcSEcCtD
Cyclophosphamide—Dermatitis—Bleomycin—skin cancer	0.000132	0.000427	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Temozolomide—skin cancer	0.000131	0.000421	CcSEcCtD
Cyclophosphamide—Urticaria—Fluorouracil—skin cancer	0.00013	0.000418	CcSEcCtD
Cyclophosphamide—Leukopenia—Docetaxel—skin cancer	0.000129	0.000417	CcSEcCtD
Cyclophosphamide—Body temperature increased—Fluorouracil—skin cancer	0.000129	0.000416	CcSEcCtD
Cyclophosphamide—Palpitations—Docetaxel—skin cancer	0.000128	0.000411	CcSEcCtD
Cyclophosphamide—Asthenia—Temozolomide—skin cancer	0.000127	0.00041	CcSEcCtD
Cyclophosphamide—Cough—Docetaxel—skin cancer	0.000126	0.000406	CcSEcCtD
Cyclophosphamide—Pruritus—Temozolomide—skin cancer	0.000125	0.000404	CcSEcCtD
Cyclophosphamide—Convulsion—Docetaxel—skin cancer	0.000125	0.000403	CcSEcCtD
Cyclophosphamide—Nausea—Bleomycin—skin cancer	0.000125	0.000402	CcSEcCtD
Cyclophosphamide—Hypertension—Docetaxel—skin cancer	0.000125	0.000402	CcSEcCtD
Cyclophosphamide—Vomiting—Dactinomycin—skin cancer	0.000125	0.000402	CcSEcCtD
Cyclophosphamide—Rash—Dactinomycin—skin cancer	0.000124	0.000398	CcSEcCtD
Cyclophosphamide—Chest pain—Docetaxel—skin cancer	0.000123	0.000396	CcSEcCtD
Cyclophosphamide—Myalgia—Docetaxel—skin cancer	0.000123	0.000396	CcSEcCtD
Cyclophosphamide—Arthralgia—Docetaxel—skin cancer	0.000123	0.000396	CcSEcCtD
Cyclophosphamide—Diarrhoea—Temozolomide—skin cancer	0.000121	0.000391	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Fluorouracil—skin cancer	0.00012	0.000388	CcSEcCtD
Cyclophosphamide—Confusional state—Docetaxel—skin cancer	0.000119	0.000383	CcSEcCtD
Cyclophosphamide—Oedema—Docetaxel—skin cancer	0.000118	0.00038	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Docetaxel—skin cancer	0.000118	0.00038	CcSEcCtD
Cyclophosphamide—Dizziness—Temozolomide—skin cancer	0.000117	0.000378	CcSEcCtD
Cyclophosphamide—Infection—Docetaxel—skin cancer	0.000117	0.000377	CcSEcCtD
Cyclophosphamide—Nausea—Dactinomycin—skin cancer	0.000116	0.000375	CcSEcCtD
Cyclophosphamide—Shock—Docetaxel—skin cancer	0.000116	0.000374	CcSEcCtD
Cyclophosphamide—Pruritus—Fluorouracil—skin cancer	0.000116	0.000372	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Docetaxel—skin cancer	0.000115	0.000372	CcSEcCtD
Cyclophosphamide—Tachycardia—Docetaxel—skin cancer	0.000115	0.000371	CcSEcCtD
Cyclophosphamide—Vomiting—Temozolomide—skin cancer	0.000113	0.000363	CcSEcCtD
Cyclophosphamide—Anorexia—Docetaxel—skin cancer	0.000112	0.000362	CcSEcCtD
Cyclophosphamide—Rash—Temozolomide—skin cancer	0.000112	0.00036	CcSEcCtD
Cyclophosphamide—Diarrhoea—Fluorouracil—skin cancer	0.000112	0.00036	CcSEcCtD
Cyclophosphamide—Dermatitis—Temozolomide—skin cancer	0.000112	0.00036	CcSEcCtD
Cyclophosphamide—Headache—Temozolomide—skin cancer	0.000111	0.000358	CcSEcCtD
Cyclophosphamide—Hypotension—Docetaxel—skin cancer	0.00011	0.000355	CcSEcCtD
Cyclophosphamide—Dizziness—Fluorouracil—skin cancer	0.000108	0.000348	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000107	0.000346	CcSEcCtD
Cyclophosphamide—Paraesthesia—Docetaxel—skin cancer	0.000106	0.000341	CcSEcCtD
Cyclophosphamide—Nausea—Temozolomide—skin cancer	0.000105	0.000339	CcSEcCtD
Cyclophosphamide—Dyspnoea—Docetaxel—skin cancer	0.000105	0.000339	CcSEcCtD
Cyclophosphamide—Vomiting—Fluorouracil—skin cancer	0.000104	0.000335	CcSEcCtD
Cyclophosphamide—Rash—Fluorouracil—skin cancer	0.000103	0.000332	CcSEcCtD
Cyclophosphamide—Dermatitis—Fluorouracil—skin cancer	0.000103	0.000332	CcSEcCtD
Cyclophosphamide—Decreased appetite—Docetaxel—skin cancer	0.000102	0.00033	CcSEcCtD
Cyclophosphamide—Headache—Fluorouracil—skin cancer	0.000102	0.00033	CcSEcCtD
Cyclophosphamide—Fatigue—Docetaxel—skin cancer	0.000102	0.000328	CcSEcCtD
Cyclophosphamide—Pain—Docetaxel—skin cancer	0.000101	0.000325	CcSEcCtD
Cyclophosphamide—Constipation—Docetaxel—skin cancer	0.000101	0.000325	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Docetaxel—skin cancer	9.71e-05	0.000313	CcSEcCtD
Cyclophosphamide—Nausea—Fluorouracil—skin cancer	9.7e-05	0.000313	CcSEcCtD
Cyclophosphamide—Body temperature increased—Docetaxel—skin cancer	9.32e-05	0.0003	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Docetaxel—skin cancer	8.68e-05	0.00028	CcSEcCtD
Cyclophosphamide—Asthenia—Docetaxel—skin cancer	8.45e-05	0.000273	CcSEcCtD
Cyclophosphamide—Pruritus—Docetaxel—skin cancer	8.34e-05	0.000269	CcSEcCtD
Cyclophosphamide—Diarrhoea—Docetaxel—skin cancer	8.06e-05	0.00026	CcSEcCtD
Cyclophosphamide—Dizziness—Docetaxel—skin cancer	7.79e-05	0.000251	CcSEcCtD
Cyclophosphamide—Vomiting—Docetaxel—skin cancer	7.49e-05	0.000242	CcSEcCtD
Cyclophosphamide—Rash—Docetaxel—skin cancer	7.43e-05	0.00024	CcSEcCtD
Cyclophosphamide—Dermatitis—Docetaxel—skin cancer	7.42e-05	0.000239	CcSEcCtD
Cyclophosphamide—Headache—Docetaxel—skin cancer	7.38e-05	0.000238	CcSEcCtD
Cyclophosphamide—Nausea—Docetaxel—skin cancer	7e-05	0.000226	CcSEcCtD
